Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification

NCT03365882 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT03365882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03365882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Completed
Start date
November 27, 2017
Completion date
July 1, 2025
Enrollment
240 (actual)
Sites
798

Conditions

As the registry lists them; a condition with its own page is linked.

colon adenocarcinoma, erbb2 gene amplification, rectal adenocarcinoma, recurrent colon carcinoma, recurrent rectal carcinoma, stage iii colon cancer ajcc v7, stage iii rectal cancer ajcc v7, stage iiia colon cancer ajcc v7, stage iiia rectal cancer ajcc v7, stage iiib colon cancer ajcc v7, stage iiib rectal cancer ajcc v7, stage iiic colon cancer ajcc v7, stage iiic rectal cancer ajcc v7, stage iv colon cancer ajcc v7, stage iv rectal cancer ajcc v7, stage iva colon cancer ajcc v7, stage iva rectal cancer ajcc v7, stage ivb colon cancer ajcc v7, stage ivb rectal cancer ajcc v7